ArticleBrain, behavior, and immunity2026
Contribution of proneurotrophin-3 to nerve trauma-induced neuropathic pain through promoting TrkC-mediated increase of CCL2 in primary sensory neurons.
Article in Brain, behavior, and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Neuropathic pain induced by nerve trauma remains a substantial and unresolved clinical challenge. Despite ongoing research, therapeutic options for this disorder remain inadequate. Here, we report that neurotrophin-3 (Nt3) mRNA and its encoded proneurotrophin-3 (proNT3) protein are upregulated in neurons of the injured dorsal root ganglion (DRG), but not in the spinal cord, following peripheral nerve trauma. Mature neurotrophin-3 (NT3) protein is undetectable in the DRG under both normal and nerve trauma conditions. Genetic blockage of Nt3 mRNA/proNT3 protein upregulation in the injured DRG attenuates the development and maintenance of nerve trauma-induced neuropathic pain, without impacting acute/basal pain responses or locomotor function. Conversely, mimicking nerve trauma-induced upregulation of DRG Nt3 mRNA/pro-NT3 produces neuropathic pain-like symptoms. These symptoms are mitigated by intrathecal injection of NT3 protein or by selective knockdown of tropomyosin receptor kinase C (TrkC), but not TrkA or TrkB, in the DRG. Notably, intrathecal injection of NT3 also alleviates nerve trauma-induced neuropathic pain. Mechanistically, upregulated proNT3 contributes to the nerve trauma-induced increases of C-C chemokine ligand 2 (Ccl2) mRNA and CCL2 protein through activating TrkC in the injured DRG. Given that CCL2 is a key driver in neuropathic pain genesis and that Nt3 mRNA co-expresses with TrkC and Ccl2 mRNA in DRG neurons, proNT3 likely participates in nerve trauma-induced neuropathic pain through promoting TrkC-mediated increase of CCL2 in DRG neurons, highlighting a potential therapeutic target for the treatment of this disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.